{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:08:15Z","timestamp":1788822495127,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wenzhou Key Laboratory of Tumor Molecular Markers","award":["2022HZSY0041"],"award-info":[{"award-number":["2022HZSY0041"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82272404"],"award-info":[{"award-number":["82272404"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82172358"],"award-info":[{"award-number":["82172358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Science and Technology Bureau","doi-asserted-by":"crossref","award":["Y2020156"],"award-info":[{"award-number":["Y2020156"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01497-9","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:54:29Z","timestamp":1779281669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Earlier postoperative ctDNA detection predicts recurrence and adjuvant therapy benefit in stage II-III colorectal cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Wenwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengquan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenni","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangchao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"1497_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics,. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1497_CR2","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L. et al. Colorectal cancer statistics,. CA Cancer J. Clin. 73, 233\u2013254 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"1497_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s, G. et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291\u20131305 (2020).","journal-title":"Ann. Oncol."},{"key":"1497_CR4","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the Mosaic trial. J. Clin. Oncol. 27, 3109\u20133116 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1497_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter, N. N. et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J. Clin. Oncol. 40, 892\u2013910 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1497_CR6","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Colon cancer [version 4.2025]. Accessed August 11, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"key":"1497_CR7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","volume":"370","author":"R Gray","year":"2007","unstructured":"Gray, R. et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370, 2020\u20132029 (2007).","journal-title":"Lancet"},{"key":"1497_CR8","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andr\u00e9","year":"2015","unstructured":"Andr\u00e9, T. et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to Braf mutation and mismatch repair status of the Mosaic study. J. Clin. Oncol. 33, 4176\u20134187 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1497_CR9","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1245\/s10434-023-13631-z","volume":"30","author":"MC Ginesi","year":"2023","unstructured":"Ginesi, M. C. et al. Factors associated with receipt of adjuvant chemotherapy in stage II colon cancer. Ann. Surg. Oncol. 30, 5511\u20135518 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"1497_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ijc.33203","volume":"148","author":"P Achilli","year":"2021","unstructured":"Achilli, P. et al. Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: analysis of the National Cancer Database. Int. J. Cancer 148, 161\u2013169 (2021).","journal-title":"Int. J. Cancer"},{"key":"1497_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ijc.30053","volume":"139","author":"SR Verhoeff","year":"2016","unstructured":"Verhoeff, S. R. et al. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int. J. Cancer 139, 187\u2013193 (2016).","journal-title":"Int. J. Cancer"},{"key":"1497_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"1497_CR13","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1497_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized dynamic trial. Nat. Med. 31, 1509\u20131518 (2025).","journal-title":"Nat. Med."},{"key":"1497_CR15","doi-asserted-by":"publisher","first-page":"346ra392","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra392 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1497_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29, 127\u2013134 (2023).","journal-title":"Nat. Med."},{"key":"1497_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen, T. V. et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin. Cancer Res. 28, 507\u2013517 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1497_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","volume":"35","author":"TV Henriksen","year":"2024","unstructured":"Henriksen, T. V. et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Ann. Oncol. 35, 229\u2013239 (2024).","journal-title":"Ann. Oncol."},{"key":"1497_CR19","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1158\/1078-0432.CCR-17-0510","volume":"23","author":"LV Sch\u00f8ler","year":"2017","unstructured":"Sch\u00f8ler, L. V. et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin. Cancer Res. 23, 5437\u20135445 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1497_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114314","volume":"211","author":"A Frydendahl","year":"2024","unstructured":"Frydendahl, A. et al. Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients. Eur. J. Cancer 211, 114314 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1497_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10863-w","volume":"23","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer. BMC Cancer 23, 422 (2023).","journal-title":"BMC Cancer"},{"key":"1497_CR22","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.ejca.2015.08.016","volume":"51","author":"AC Bos","year":"2015","unstructured":"Bos, A. C. et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur. J. Cancer 51, 2553\u20132561 (2015).","journal-title":"Eur. J. Cancer"},{"key":"1497_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00432-018-2701-x","volume":"144","author":"DH Murray","year":"2018","unstructured":"Murray, D. H. et al. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J. Cancer Res. Clin. Oncol. 144, 1741\u20131750 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1497_CR24","doi-asserted-by":"crossref","unstructured":"Jin, S. et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc. Natl. Acad. Sci. USA. 118 (2021).","DOI":"10.1073\/pnas.2017421118"},{"key":"1497_CR25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/jamaoncol.2023.0425","volume":"9","author":"S Mo","year":"2023","unstructured":"Mo, S. et al. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA Oncol. 9, 770\u2013778 (2023).","journal-title":"JAMA Oncol."},{"key":"1497_CR26","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272\u20133283 (2024).","journal-title":"Nat. Med."},{"key":"1497_CR27","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","volume":"112","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi, H. et al. Circulate-japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 112, 2915\u20132920 (2021).","journal-title":"Cancer Sci."},{"key":"1497_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.21147\/j.issn.1000-9604.2024.04.07","volume":"36","author":"W Pu","year":"2024","unstructured":"Pu, W. et al. Potential value of detection of minimal residual disease in colorectal cancer following radical resection. Chin. J. Cancer Res. 36, 442\u2013454 (2024).","journal-title":"Chin. J. Cancer Res."},{"key":"1497_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.120026","volume":"565","author":"D Zhu","year":"2025","unstructured":"Zhu, D. et al. Highly specific multiplex DNA methylation detection for liquid biopsy of colorectal cancer. Clin. Chim. Acta 565, 120026 (2025).","journal-title":"Clin. Chim. Acta"},{"key":"1497_CR30","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-24-3200","volume":"31","author":"TV Henriksen","year":"2025","unstructured":"Henriksen, T. V. et al. Timing of ctDNA analysis aimed at guiding adjuvant treatment in colorectal cancer. Clin. Cancer Res. 31, 1676\u20131685 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1497_CR31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamasurg.2015.0871","volume":"150","author":"P Thirunavukarasu","year":"2015","unstructured":"Thirunavukarasu, P. et al. Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. Jama. Surg. 150, 747\u2013755 (2015).","journal-title":"Jama. Surg."},{"key":"1497_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/jama.2013.285718","volume":"311","author":"JN Primrose","year":"2014","unstructured":"Primrose, J. N. et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACs randomized clinical trial. JAMA 311, 263\u2013270 (2014).","journal-title":"JAMA"},{"key":"1497_CR33","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1001\/jama.2018.5623","volume":"319","author":"P Wille-J\u00f8rgensen","year":"2018","unstructured":"Wille-J\u00f8rgensen, P. et al. Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: The colofol randomized clinical trial. JAMA 319, 2095\u20132103 (2018).","journal-title":"JAMA"},{"key":"1497_CR34","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaoncol.2019.0512","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer. JAMA Oncol. 5, 1118\u20131123 (2019).","journal-title":"JAMA Oncol."},{"key":"1497_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10699-4","volume":"23","author":"S Slater","year":"2023","unstructured":"Slater, S. et al. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC part c). BMC Cancer 23, 257 (2023).","journal-title":"BMC Cancer"},{"key":"1497_CR36","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona, N. et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann. Oncol. 30, 1804\u20131812 (2019).","journal-title":"Ann. Oncol."},{"key":"1497_CR37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamasurg.2024.1555","volume":"159","author":"M G\u00f6genur","year":"2024","unstructured":"G\u00f6genur, M. et al. Time from colorectal cancer surgery to adjuvant chemotherapy: Post hoc analysis of the Scot randomized clinical trial. JAMA Surg. 159, 865\u2013871 (2024).","journal-title":"JAMA Surg."},{"key":"1497_CR38","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2024.08.2240","volume":"35","author":"K Kataoka","year":"2024","unstructured":"Kataoka, K. et al. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from Circulate-Japan Galaxy. Ann. Oncol. 35, 1015\u20131025 (2024).","journal-title":"Ann. Oncol."},{"key":"1497_CR39","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi, A. et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 chronos trial. Nat. Med. 28, 1612\u20131618 (2022).","journal-title":"Nat. Med."},{"key":"1497_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07252-y","volume":"20","author":"SJ Schraa","year":"2020","unstructured":"Schraa, S. J. et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (medocc-create): Study protocol for a trial within a cohort study. BMC Cancer 20, 790 (2020).","journal-title":"BMC Cancer"},{"key":"1497_CR41","doi-asserted-by":"crossref","unstructured":"Sinicrope, F. A. et al. Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of folfox-based adjuvant chemotherapy (alliance n0147). J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. JCO2502086 (2026).","DOI":"10.2139\/ssrn.5397500"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01497-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:35:16Z","timestamp":1788820516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01497-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01497-9","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: C.D. is a founder for Innovation Biomed Co., Ltd. J. Luan is an employee of Innovation Biomed Co., Ltd. C.D., S.J., J.W., Z.Y., and J. Luan have filed patent applications for the mqMSP assay (Application No.: PCT\/CN2023\/121392, No.: 202380096841.4). The patent applicant is Innovation Biomed Co., Ltd, and the inventors include C.D., S.J., J.W., Z.Y., and J. Luan. The Chinese application (Application No.: 202380096841.4) has been published and has entered substantive examination. The corresponding applications are currently pending. The patent covers the mqMSP-based ctDNA methylation assay for minimal residual disease detection and recurrence risk assessment. The other authors have no competing financial or non-financial interests to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"345"}}